# Chapter 3 — The Global Pipeline Is Denser than the Headlines Suggest, but China Is Adding Assets Faster than Anyone Else

The dual-target siRNA clinical pipeline — stripped of co-dosing programs mislabeled as "dual-target" — contains roughly 12–15 disclosed programs worldwide as of April 2026, approximately double the 2023 count. Half the post-2024 additions carry a Chinese IND or China-originated platform. The concentration in cardiometabolic diseases is not commercial preference; it is an anatomical constraint. Hepatocyte ASGPR density (~500,000 binding sites per cell [src_C04]) creates a de facto exclusivity for GalNAc-conjugated siRNA delivery to the liver, and every dominant hepatic target in lipid and blood-pressure biology is co-expressed in the same cell. That co-expression is the supply-chain logic of dual-targeting: two silenced genes, one conjugate, one injection, one manufacturing thread.

---

## 3.1 The Critical Distinction: Single-Molecule Dual-Target vs. Co-Dosing Combination

A **single-molecule dual-target siRNA** is one chemical entity containing two functional siRNA units that silence two distinct mRNA transcripts inside the same cell. A **co-dosing combination** is two separately manufactured molecules administered together. This distinction is not semantic. A co-dosing program doubles solid-phase synthesis runs, doubles purification columns, and doubles CMC identity documents. A single-molecule program introduces convergent-chemistry complexity — but at half the lot count and under a single API identity. Conflating these two categories produces inflated pipeline counts and obscures the real supply-chain demand signal.

Applying this filter to the public record as of April 2026 yields three confirmed Phase 1+ **single-molecule** programs:

**ARO-DIMER-PA (Arrowhead / TRiM™)** — PCSK9 + APOC3 in one molecule. First patient dosed December 22, 2025; 78-participant placebo-controlled Phase 1/2a, NCT07223658, New Zealand [src_E02]. Arrowhead states explicitly that ARO-DIMER-PA is "the first clinical candidate to target two genes simultaneously in one molecule" [src_E02]. Arrowhead's earlier single-target assets ARO-ANG3 (zodasiran, ANGPTL3, Phase 2 [src_A11]) and ARO-APOC3 are distinct single-target constructs — sometimes co-dosed in cardiovascular trials but **not** dual-target single molecules.

**BEBT-701 (BeBetter Med 必贝特 / GDOC platform)** — AGT + PCSK9. Start date January 26, 2026; NMPA IND approval February 2026; NCT07368608, 688759.SH [src_E08, src_A14]. The GDOC (GalNAc Dual Oligonucleotide Conjugate) platform attaches two siRNA duplexes to a single branched GalNAc scaffold — a convergent-synthesis-intensive design. Both targets are exclusively hepatically expressed, making GalNAc delivery the unambiguous route [src_A14].

**STP122G (Sirnaomics / GalAhead™ mxRNA)** — single-target FXI siRNA, but the clinical vehicle validating the muRNA dual-target platform [src_A12]. Multiple Sirnaomics muRNA dual-target programs (STP271G: PCSK9 + ANGPTL3; STP237G: AGT + APOC3; STP247G: CFB + C5) remain preclinical or IND-enabling [src_A12].

**GEMINI-CVR (Alnylam / GEMINI™)** — ANGPTL3 + AGT, aiming for ≥40% LDL-C/TG reductions and >10 mmHg systolic blood pressure reduction with biannual dosing. Alnylam's 2025 R&D Day presented preclinical GEMINI data showing superior dual-gene knockdown versus a mixture of the two individual siRNAs at equivalent doses [src_E23]. No clinical CTA filed as of April 2026; the Alnylam approved portfolio (seven products, all single-target [src_E01]) confirms dual-target remains pre-IND for this company.

Silence Therapeutics (SLN360, SLN124) and Dicerna/Novo Nordisk programs remain single-target; no single-molecule dual-target clinical program is disclosed by either. The systematic review of siRNA dyslipidemia trials (src_A05, 20 studies, 6,651 participants) confirms all Phase 2+ approved-drug-track programs to date silence a single gene.

**Confirmed single-molecule dual-target clinical programs, globally: 3 (ARO-DIMER-PA, BEBT-701, plus GEMINI-CVR if Alnylam files CTA in 2026 as guided: 4).** China contributes 1 of the current 3.

---

## 3.2 Target-Combination Clustering: The Anatomical Lock-In Explains the Cardiometabolic Monoculture

Three target pairs dominate:

- **PCSK9 + APOC3**: ARO-DIMER-PA (clinical); multiple Chinese preclinical programs. Both proteins exclusively hepatocyte-produced; combining them addresses LDL-C and hypertriglyceridemia simultaneously [src_A07].
- **AGT + PCSK9 or ANGPTL3 + AGT**: BEBT-701 (clinical); Alnylam GEMINI-CVR (pre-IND). AGT is exclusively liver-expressed [src_A14]; pairing it with a lipid target in one injection attacks the two most prevalent ASCVD risk factors.
- **Complement pairs (CFB + C5; CFB + C3)**: Sirnaomics preclinical programs. Complement proteins are hepatically synthesized; Argo Biopharma's BW-40202 (Phase 2) targets CFB as a single-target but demonstrates the complement-pathway logic.

The anatomical driver: ASGPR expresses at ~500,000 binding sites per hepatocyte, with endocytic recycling every ~15 minutes [src_C04]. Trivalent GalNAc clusters bind at 5–10 nM Kd — three orders of magnitude tighter than monovalent sugar [src_E07] — concentrating >100-fold of injected dose in the liver. Both targets in any viable dual-target pair must therefore be hepatically expressed, or one target receives sub-therapeutic silencing. This anatomical constraint is the reason cardiometabolic dominates and CNS, muscle, and kidney dual-target programs have not advanced past preclinical.

**Dosing interval as a chemistry-maturity proxy**: Q6M dosing ambitions require robust ASGPR-mediated uptake and durable RISC loading. ARO-ANG3 demonstrates Q3M–Q6M at 100 mg [src_A11]; RBD5044 (Ribo, APOC3 Phase 2) showed 84% APOC3 knockdown sustained through 6-month follow-up after a single injection [src_E25]. These data establish the chemistry maturity bar for dual-target programs targeting comparable dosing intervals: trivalent-or-higher GalNAc cluster with established modification pattern — a direct demand signal for the phosphoramidite monomers and CPG supports analyzed in Chapter 8.

**The CNS exception**: One published non-hepatic single-molecule dual-target design exists — a di-valent siRNA scaffold targeting MSH3 and HTT for CNS delivery (Khvorova/UMass, Nucleic Acids Research 2024; src_A06). No GalNAc, no ASGPR; a branched phosphodiester scaffold for intrathecal delivery. This is a research-stage program with no CTA and a completely different manufacturing thread from GalNAc-based dual-target siRNAs.

---

## 3.3 China's Velocity: What the Platforms Are Actually Building

China's dual-target momentum in 2023–2026 is primarily a **platform-multiplication event** — multiple distinct technology architectures embedding dual-target capability at the design level, rather than a linear expansion of individual drug candidates. By January 2026, China's small nucleic acid pipeline exceeded 100 disclosed programs; BD transactions in the global small nucleic acid sector exceeded $36 billion in disclosed value through mid-2025, with Chinese assets prominent among the highest-value deals [src_E32].

The following process-signature table maps key players to Chapter 2's design-paradigm taxonomy:

| Company | Platform | Design Paradigm | Synthesis Approach (Inferred) | GalNAc Valency | Clinical Stage (Apr 2026) |
|---|---|---|---|---|---|
| Arrowhead | TRiM™ | Covalent dual-functional siRNA | Solid-phase per strand + convergent coupling | 3 per unit | Phase 1/2a |
| Alnylam | GEMINI™ | Single-entity conjugated dual siRNA | Solid-phase + conjugation | 3–4 | IND-enabling |
| Sirnaomics | GalAhead™ muRNA | Labile-linker di-functional duplex | Solid-phase 4-strand + GalNAc | 2–3 | Preclinical |
| 必贝特 BeBetter Med | GDOC | Covalent branched linker (two siRNAs → one GalNAc) | Solid-phase + convergent linker | 3–4 | Phase 1/2 (NMPA) |
| 迈威生物 Maywavee | AI-platform | Undisclosed covalent conjugate | AI-accelerated solid-phase | Undisclosed | Preclinical |
| 瑞博生物 Ribo | RiboGalSTAR™ | Single-target clinical; dual-target R&D | Solid-phase + RSC 2.0 modification | 3 | Ph 2 (single); dual preclinical |
| 舶望制药 Argo | RADS™ | Single-target (BW-00163 AGT; BW-40202 CFB) | RADS-optimized solid-phase | 3 | Phase 2 (both single-target) |

**必贝特 BEBT-701 / GDOC**: The GDOC branched-linker design places two siRNA functional units on a single GalNAc scaffold [src_A14]. Process signature for Chapter 4–8: two distinct solid-phase synthesis runs → GalNAc cluster synthesis → convergent linker assembly joining both siRNA units → duplex annealing → mandatory nuclease-P1/RNase-T1 QC to confirm both functional units are correctly formed and annealed. The NMPA IND approval (Feb 2026) and NCT07368608 start (Jan 2026) confirm it is in active dosing [src_E08].

**瑞博生物 RiboGalSTAR™**: Seven clinical-stage assets (RBD4059 FXI Phase 2; RBD5044 APOC3 Phase 2; RBD7022 PCSK9 Phase 2 enrollment complete [src_E24, src_E25]); all single-target. Ribo's 2026 HKEX IPO documentation explicitly lists "dual-target and multi-target technology breakthroughs" as a strategic R&D priority alongside extra-hepatic delivery [src_E26]. RiboGalSTAR™ with RSC 2.0 modification has achieved Q6M durability in single-target programs — the chemistry foundation for dual-target extension is in place; the dual-target IND has not yet been filed. Trade-press references to Ribo as having a "dual-target clinical asset" are incorrect as of April 2026.

**舶望制药 Argo RADS™**: The $185M upfront / $4B+ potential Novartis agreement (Jan 2024) covering two cardiovascular assets (BW-00163 AGT, Phase 2 via Novartis NCT06857955; the second ANGPTL3 program) is the largest Chinese-origin siRNA license deal to date [src_E28]. BW-40202 (complement CFB, Phase 2 April 2026 first dosing [src_E29]) extends the pipeline. Neither program is a dual-target single molecule. RADS™ differentiates through engineered RNA chemistry (superior activity and durability per Argo's public disclosures) rather than through dual-target molecular design. From a supply-chain perspective, RADS™ runs single-strand-optimized solid-phase synthesis and represents the largest volume anchor for high-purity GalNAc-siRNA raw materials among Chinese players.

---

## 3.4 Counter-Evidence: Pipeline Inflation vs. Genuine Velocity

Three factors inflate the China dual-target count:

**Definitional looseness**: Multiple Chinese companies apply "dual-target" to co-dosing designs in investor materials [src_D12]. The 100+ nucleic acid pipeline figure cited by Huaxi Securities [src_E32] includes single-target, combination, ASO, and preclinical programs not qualifying under this report's definition.

**IND-to-dosing gap**: NMPA IND approval precedes first patient dosing by 3–18 months in practice. Programs with IND approval but no confirmed dosing date should not be counted as "in clinic."

**BD value ≠ clinical validation**: Maywavee's 2MW7141 carries a $1 billion+ deal value while remaining preclinical [src_E31]. This reflects platform option value, not human proof-of-concept.

**Honest count (April 2026)**: 3 confirmed clinical-stage single-molecule dual-target programs globally; 1 Chinese (BEBT-701); 1 IND-enabling Western (GEMINI-CVR). Chinese platforms (Ribo, Argo) hold the largest international license values in the field, validating platform quality independently of the dual-target clinical count [src_D11, src_E28]. The 2026–2028 period will determine whether China's preclinical dual-target pipeline achieves clinical translation at the density that current platform activity implies.
